Neuroscience Program and College of Medicine, University of Illinois, Urbana-Champaign, IL 61801, USA.
Curr Protein Pept Sci. 2012 Jun;13(4):358-71. doi: 10.2174/138920312801619420.
We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
我们首先回顾脆性 X 综合征的首次特征描述,这最终导致了 FMR1 基因的克隆。这一疾病的分子基础的发现,包括三核苷酸重复序列的扩展,不仅为脆性 X 综合征,也为前突变综合征提供了深入了解。本文讨论了脆性 X 综合征的特征,包括患者表型直至神经元表型。描述了脆性 X 智力迟钝蛋白 FMRP 的结构域特征,以及与 FMRP 结合的 mRNAs 以及翻译后修饰作为 FMRP 功能调节剂的作用。还回顾了 FMRP 在祖细胞中的相对新作用,以及 FMRP 在细胞中的定位以及 FMRP 如何受大脑中谷氨酸能信号的调节。了解代谢型谷氨酸受体如何影响 FMRP 已导致治疗这种疾病的新的治疗方法。